Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Skin Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1428152
This article is part of the Research Topic Management of Rare Oncological Cases View all 37 articles

Case Report: Conjunctival Melanoma Treated with Relatlimab and Nivolumab Showing Remarkable Response

Provisionally accepted
Mirona Attrash Mirona Attrash 1Omar Badran Omar Badran 1Yinon Shapira Yinon Shapira 2,3Gil Bar-Sela Gil Bar-Sela 1,2*
  • 1 Ha'Emek Medical Center, Afula, Israel
  • 2 Technion Israel Institute of Technology, Haifa, Israel
  • 3 Department of Ophthalmology, Carmel Medical Center, Haifa, Israel

The final, formatted version of the article will be published soon.

    Conjunctival melanoma, an uncommon form of ocular melanoma, shares some molecular characteristics with cutaneous melanoma and some with mucosal melanoma. Treatment of cases where it becomes advanced or metastatic raises unique treatment challenges. Nivolumab/relatlimab (Opdualag) recently received FDA approval for metastatic melanoma based on the phase 2/3 RELATIVITY-047 trial, which showed better median progression-free survival (PFS) in the first-line setting without new safety signals. The efficacy of this drug in conjunctival melanoma has not been reported yet. Case presentation: An 87-year-old woman with a history of mild dementia was admitted to the oncology department with a large, exophytic tumor protruding from her left eye, diagnosed as conjunctival melanoma two years previously. This tumor was secreting a whitish fluid and obstructing her vision. Immunotherapy with Opdualag was started, with a near clinical complete response after the 1 st cycle. The patient was treated with only four cycles due to worsening of her dementia. Conclusion:Nivolumab/relatlimab (Opdualag) is a promising treatment alternative in conjunctival melanoma when surgery is not viable.

    Keywords: Conjunctival Melanoma, Nivolumab/Relatlimab, Opdualag, Immunotherapy, cognitive health

    Received: 05 May 2024; Accepted: 26 Aug 2024.

    Copyright: © 2024 Attrash, Badran, Shapira and Bar-Sela. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Gil Bar-Sela, Technion Israel Institute of Technology, Haifa, Israel

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.